In July 2020, the authors started a randomized control trial (NCT04425226) to evaluate the safety and efficacy of PD-1 inhibitor in combination with lenvatinib as neoadjuvant therapy in participants with hepatocellular carcinoma (HCC) before LT. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.